Avesthagen's ABRPL Gets RCGM's Nod for Pre-Clinical Evaluation of Biopharmaceutical Products

Avesthagen announced the permission to Avesta Biotherapeutics & Research Private Limited (ABRPL) to enter into a pivotal pre-clinical safety and efficacy evaluation study for three of its biopharmaceutical product development programs. The Review Committee for Genetic Manipulation (RCGM) authorized by the Department of Biotechnology, Govt. of India has approved ABRPL's applications for conducting a pre-clinical evaluation of the these biopharmaceutical products at recognized contract research facilities. These biopharmaceutical products are being developed as per global regulatory standards by ABRPL, a joint venture between Avesthagen Limited and Meditab Specialities, and are targeted at important therapeutic indications namely, rheumatoid arthritis, anemia resulting from chronic renal failure or chemotherapy and colorectal cancer. Company sources revealed that said products will progress to clinical evaluation during early 2009 based on the outcome of the pre-clinical evaluation. It is an attempt to provide advanced therapeutic solutions at affordable cost that are currently out of reach for almost all Indian patients.